First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis

First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Jing-Wen Han, Yu Zhong, Jin Zhong, Wen-Jing Zeng, Li-Jun Sun
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151424/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.
by: Jing-Wen Han, et al.
Published: (2025-01-01)

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma
by: Qi Wang, et al.
Published: (2025-07-01)

Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
by: Ming Ouyang, et al.
Published: (2025-08-01)

Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China
by: Fang Chen, et al.
Published: (2023-12-01)

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study
by: Ning Li, et al.
Published: (2024-11-01)

Sugemalimab plus chemotherapy vs. chemotherapy for treatment of Chinese patients with esophageal squamous cell carcinoma: a cost effectiveness analysis to inform decision making
by: Qiuping Chen, et al.
Published: (2025-06-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Neoadjuvant toripalimab combined with chemotherapy in locally advanced HNSCC
by: Zhaoyang Wang, et al.
Published: (2025-05-01)

Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
by: Zhiwei Zheng, et al.
Published: (2025-01-01)

Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China
by: Shuo Kang, et al.
Published: (2025-01-01)

Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.
by: Shuo Kang, et al.
Published: (2025-01-01)

First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy
by: L. V. Bolotina, et al.
Published: (2019-01-01)

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
by: Ling Fang, et al.
Published: (2023-12-01)

[Cost Evaluation of First-Year Treatment for Locally Advanced or Metastatic Urothelial Carcinoma with Chemotherapy Plus Avelumab vs Chemotherapy Plus Best Supportive Care: A Cost of Care Model]
by: Daniela Paola Roggeri, et al.
Published: (2025-08-01)

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
by: Jia Zhong, et al.
Published: (2024-12-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study
by: Chengzhi Ding, et al.
Published: (2025-04-01)

Predictive role of inflammatory markers for the efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer
by: Chenming Zhong, et al.
Published: (2025-04-01)

Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma
by: Likun Liu, et al.
Published: (2025-08-01)

Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma
by: Qingyang Zhuang, et al.
Published: (2025-05-01)

Sequential boost of intensity‐modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study
by: Xing‐Wen Fan, et al.
Published: (2020-04-01)

Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
by: Qiang Liu, et al.
Published: (2024-03-01)

Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study
by: Jiazhen Chen, et al.
Published: (2025-08-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Shixian Liu, et al.
Published: (2025-08-01)

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01)

Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report
by: Wei Ning, et al.
Published: (2024-12-01)

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails
by: Jiashou Wang, et al.
Published: (2025-06-01)

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis
by: Kai Xu, et al.
Published: (2025-12-01)

Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report
by: Ying Sun, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

The genomic landscape of esophageal squamous cell carcinoma cell lines
by: Chao Zhang, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US.
by: Ping Chen, et al.
Published: (2025-01-01)

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial
by: Ke Liu, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers
by: Can Jiang, et al.
Published: (2025-04-01)

Induction chemotherapy with cisplatin plus weekly paclitaxel followed by chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck
by: Sargeele Silva, et al.
Published: (2019-01-01)